

throiditis, graft rejection, including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinophilic myotitis, eosinophilic fasciitis; and cancers.

110. (Amended) [A] The method [to effect the binding of a] of claim 108 wherein the chemokine receptor is selected from the group consisting of: CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4], comprising administering to a mammalian subject an effective amount of the pharmaceutical composition of claim 102].

113. (Amended) A method [of use of the pharmaceutical composition of claim 102, in combination with one or more agents useful in] for the prevention or treatment of HIV, comprising administering to a mammalian subject a therapeutically effective amount of [said] a pharmaceutical composition containing an effective amount of the compound of claim 1 in combination with one or more anti-HIV agents.

114. (Amended) The method of claim 113, wherein one or more anti-HIV agents are selected from the group consisting of: a nucleotide reverse transcriptase inhibitor [such as zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine todoxil]; non-nucleotide reverse transcriptase inhibitor [(including an agent having anti-oxidation activity such as immunocal, oltipraz, etc.) such as nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, etc.;] and protease inhibitors [such as saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, palinavir, lasinavir].

Please cancel claims 115 and 116.

REMARKS

The claims have been amended to reduce the number of claims and mitigate fees. In addition, certain claims have been clarified. Claim 1 has been amended to correct an obvious typographical error in that R⁸ is clearly optionally substituted rather than substitution being

mandated. This is evident from the examples set forth in the specification, wherein the majority of cases, R⁸ is unsubstituted. The remainder of the amendments to claim 1 are simply for clarification.

Similarly, claims 2-4 and 6 are amended to clarify that optional substitution remains within the scope of the claims. Claims 12 and 13 have simply been amended for clarity.

Claim 51 has been amended for cosmetic purposes as has claim 58. With respect to claim 91, the alternative possibilities set forth in claim 92 have been inserted into that claim. Claims 97-101 have been amended to make them dependent on claim 1.

Claims 102-114 have been amended to place them in more conventional form. No new matter has been added and entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 391442003700. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: February 1, 2001

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125